Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
ESSEX WOODLANDS HEALTH VENTURES FUND VII LP
   2. Issuer Name and Ticker or Trading Symbol
Corium International, Inc. [CORI] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O ESSEX WOODLANDS HEALTH VENTURES, 335 BRYANT STREET, THIRD FLOOR		 3. Date of Earliest Transaction (Month/Day/Year)
04/08/2014
(Street)

PALO ALTO, CA 94301		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 04/08/2014   C   679,115 A (1) 679,115 D  
Common Stock 04/08/2014   C   2,028,309 A (1) 2,704,424 D  
Common Stock 04/08/2014   X   397,718 A (3) 3,105,142 D  
Common Stock 04/08/2014   X   26,385 A (3) 3,131,527 D  
Common Stock 04/08/2014   X   214,149 A (3) 3,345,676 D  
Common Stock 04/08/2014   X   1,114 A (3) 3,346,790 D  
Common Stock 04/08/2014   X   218,279 A (3) 3,565,069 D  
Common Stock 04/08/2014   X   794 A (4) 3,565,863 D  
Common Stock 04/08/2014   X   397 A (4) 3,566,260 D  
Common Stock 04/08/2014   C   3,387,146 A (5) 6,953,406 D  
Common Stock 04/08/2014   C   1,999,898 A (5) 8,953,304 D  
Common Stock 04/08/2014   P   400,000 A $ 8 9,353,304 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series B Convertible Preferred Stock (1) 04/08/2014   C     6,859,066   (1)   (1) Common Stock 679,115 (2) $ 0 0 D  
Series C Convertible Preferred Stock (1) 04/08/2014   C     20,485,926   (1)   (1) Common Stock 2,028,309 (2) $ 0 0 D  
Warrant to Purchase Common Stock (3) 04/08/2014   X     397,718   (3) 08/02/2017 Common Stock 397,718 (3) 0 D  
Warrant to Purchase Common Stock (3) 04/08/2014   X     26,385   (3) 08/02/2017 Common Stock 26,385 (3) 0 D  
Warrant to Purchase Common Stock (3) 04/08/2014   X     214,149   (3) 08/02/2017 Common Stock 214,149 (3) 0 D  
Warrant to Purchase Common Stock (3) 04/08/2014   X     1,114   (3) 08/02/2017 Common Stock 1,114 (3) 0 D  
Warrant to Purchase Common Stock (3) 04/08/2014   X     218,279   (3) 08/02/2017 Common Stock 218,279 (3) 0 D  
Warrant to Purchase Series C Convertible Preferred Stock (4) 04/08/2014   X     109,015   (4) 07/02/2020 Common Stock 794 (2) (4) 0 D  
Warrant to Purchase Series C Convertible Preferred Stock (4) 04/08/2014   X     54,507   (4) 12/29/2020 Common Stock 397 (2) (4) 0 D  
Convertible Promissory Notes (5) 04/08/2014   C     3,387,146   (5) 07/01/2017 Common Stock 3,387,146 (5) 0 (5) D  
Convertible Promissory Notes (5) 04/08/2014   C     1,999,898   (5) 07/01/2017 Common Stock 1,999,898 (5) 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
ESSEX WOODLANDS HEALTH VENTURES FUND VII LP
C/O ESSEX WOODLANDS HEALTH VENTURES
335 BRYANT STREET, THIRD FLOOR
PALO ALTO, CA 94301		     X    

Signatures

 /s/Lowell Segal, Attorney-in-fact   04/08/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into Common Stock in connection with the Issuer's initial public offering and had no expiration date.
(2) The number of shares reflects a 10.1-for-1 reverse stock split of all outstanding shares of Common Stock effected on March 21, 2014.
(3) The warrants were automatically net exercised in connection with the Issuer's initial public offering at an exercise price of $2.12100 per share.
(4) The warrants were automatically net exercised in connection with the Issuer's initial public offering at an exercise price of $7.41140 per share.
(5) The principal amount and accrued interest automatically converted into the specified number of shares of Common Stock in connection with the Issuer's initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.